ANI Pharmaceuticals Q4 2025: Strong Growth, But Execution Risks Emerge

分组1 - ANI Pharmaceuticals, Inc. reported a 4Q25 non-GAAP EPS of $2.33, exceeding consensus estimates by approximately $0.35 [1] - The company's revenue for the quarter was $247.1 million, representing a 30% year-over-year increase and surpassing expectations by about $16.07 million [1]